Many patients in the SP cohort also had diabetes (63.1%); 43.9% of patients in this cohort were taking metformin (vs. 74.8% in the PP cohort) and 47.6% were taking insulin (vs. 41.6% in the PP cohort; Figure 2). The gene discussed is INS; the disease is diabetes mellitus.